Looking for a new broker?
Passage Bio, Inc. stock is down -0.17% since 30 days ago. The next earnings date is Mar 4, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 December’s closed higher than November. 100% of analysts rate it a buy.
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysososomal acid beta-galactosidase for infantile GM1. The company also develops PBML04 for the treatment of metachromatic leukodystrophy.
